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Abstract
Mammary Serine Protease Inhibitor (Maspin) is a unique member of the serpin family
with tumor suppressive properties. Maspin is a secreted protein encoded by a class II
tumor  suppressor  gene,  expressed in  normal  prostate  luminal  and basal  cells  but
reduced or  absent  in  prostate  cancer.  Currently,  there  is  a  consensus that  maspin
expression in prostate cancer is an indicator of a better prognosis and is a predictive
marker for therapeutic response in prostate cancer. Experimental evidence consistent‐
ly  indicates  that  maspin  suppresses  tumor  growth,  invasion,  and  metastasis  and
promotes apoptosis in cancer cells. In this chapter, we discuss regulation of maspin
expression, binding partners of maspin, and pathways through which maspin exerts its
tumor suppressive properties. In addition, we summarize the progress that investiga‐
tors have made in clarifying the role of  maspin in prostate cancer biology and in
assessing its role as a diagnostic marker and therapeutic agent.
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1. Introduction
Mammary Serine Protease Inhibitor or Maspin (SERPINB5 or PI5 Homo sapiens) is a 42 kDa, non-
classical, non-inhibitory member of the ovalbumin clade of serine protease inhibitors (ser‐
pins), encoded by the SERPIN5 gene [1]. Chromosome 18 encodes maspin along with gene
cluster of other serpins in humans comprising squamous cell carcinoma antigens (SCCAs) 1 and
2 and plasminogen activator inhibitor type 2 (PAI-2) [1, 2]. Maspin has been characterized as a
class II tumor suppressor gene, first recognized in 1994, in normal mammary tissue and breast
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cancer cell lines through subtractive hybridization, comparing genes expressed in different
stages of a biological or pathological process [2]. Maspin has been shown to be downregulat‐
ed in many metastatic tumor cell lines, without evidence of an underlying mutation [3]. Maspin
contains a reactive center loop (RCL), which is used to trap the target protease and inhibit its
activity, a common characteristic of inhibitory serpins [1, 2]. Recent studies suggest that serpins
are involved in cell adhesion and play a role in extracellular remodeling [2, 3]. However, maspin
has been found to be more closely related to the non-inhibitory clade B serpins. As maspin’s
RCL is shorter than those of inhibitory serpins and unlike multiple other serpins, maspin does
not undergo a stressed-relaxed conformational change to inhibit protease activity. Despite the
reported activity as a serine protease inhibitor, several studies argue that the tumor suppres‐
sor activity of maspin is due to its ability to inhibit proteolysis. Some studies demonstrate the
efficacy of maspin in the inhibition of activity of tissue-type plasminogen activator [4]. Further‐
more, maspin has been shown to mediate the inhibition of urokinase-type plasminogen activator
(uPA) on the surface of prostate cancer cells [5]. Although maspin might lack the ability to inhibit
serine proteases, its biological function can be attributed to RCL, which can be derived from its
crystal structure [6]. Recent studies of maspin have provided evidence for its ability to regu‐
late cell adhesion, motility, apoptosis, and angiogenesis, which has been of utmost interest in
medical field attempting to use maspin as a method of therapeutic intervention for prostate
cancer and other forms of malignancies [3–7].
2. Expression of maspin in normal prostate and cancer
Maspin has been localized to the cell surface, nucleus, cytoplasm, and extracellular matrix of
epithelial cells of different tissues [8]. In normal breast and prostate epithelial cells, maspin is
highly expressed and found to be localized mostly in the cytoplasm but has also been detected
in the nucleus, secretory vesicles, and occasionally at the cell surface [6–8]. Maspin expression
is almost completely suppressed in the human prostate cancer LNCaP, DU145, and PC-3 cell
lines [9]. At the tissue level, maspin’s function seems to be directly correlated with its locali‐
zation. In benign prostate epithelium, maspin expression is uniformly noted in basal cells at
high levels. In contrast, maspin expression is predominantly absent in benign secretory cells
and elevated in secretory cells at the transition site between benign prostatic hyperplasia and
high-grade PIN lesions [9, 10]. Pierson et al. noted higher expression of maspin in HGPIN
lesions, particularly within secretory cells [11]. Elevated maspin immunoreactivity in the
secretory cells appeared at the transition area between benign prostate tissue and HGPIN,
whereas less intense maspin staining was observed in neoplastic cells adjacent to HGPIN. No
change in maspin expression was observed in the basal cells near HGPIN, compared to normal
basal cells [12]. Moreover, an inverse relationship between maspin expression and tumor
progression was noted in clinical specimens with gradual disappearance in primary prostate
cancer. Due to the loss of basal layer during prostate cancer progression, strong immunohis‐
tochemical staining of maspin was lost in the basal cells [12, 13]. A progressive decrease in
maspin expression was noted with increase in Gleason grade, with complete loss of maspin in
high grade and metastatic tumors (Figure 1). Maspin expression was significantly higher in
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tumor specimens of patients treated with neoadjuvant androgen ablation therapy before
radical prostatectomy [14]. Prostate cancer patients whose tumors expressed maspin had a
significantly longer recurrence-free survival [6, 12].
Figure 1. Expression of maspin in various representative human prostate specimens. Paraffin-embedded (4.0 μm) sec‐
tions from benign A, and prostate cancer of various Gleason grades B–D, were used for maspin expression by immu‐
nohistochemistry. A strong nuclear and cytoplasmic staining was observed in benign tissue where the basal cell
cytoplasm and nuclei were strongly and uniformly immunoreactive for maspin. Less intense cytoplasmic staining was
noted in secretory cells. In low-grade cancer (Gleason grade 3), loss of nuclear maspin staining was observed and tu‐
mors progressively exhibited reduced maspin expression where the majority of high-grade tumors exhibit little or no
cytoplasmic immunoreactivity. Magnified at ×20 and inset ×40.
3. Regulation of maspin expression
Maspin expression is regulated by a promoter with two response elements—Ets and a
promiscuous hormone response element that binds glucocorticoid receptor and progesterone
receptor [15]. Regulation of maspin by androgen receptor (AR) seems complex because the
hormone response element of maspin’s promoter appears to function as a negative regulator.
Zou et al. have demonstrated that androgen-responsive LNCaP cells cultured in androgen-
depleted medium exhibit induction of maspin promoter activity in a promoter luciferase
reporter assay [16]. Furthermore, castration of nude mice induces maspin expression in LNCaP
xenograft tumors. These data indicate that maspin may be transiently upregulated in early
stages of prostate tumor development and remains sensitive to AR repression.
Another major regulatory mechanism for maspin is the involvement of p53 signaling pathway
[16]. A consensus p53 site was identified in the maspin promoter, which induced its expression
upon binding to p53. Maspin expression was increased in adenoviral-mediated expression of
wild-type p53 in maspin-null prostate cancer cell lines. During cellular stress, p53-responsive
pathways were induced in cells possessing wild-type p53, whereas mutant p53 failed to induce
its expression. Purified p53 protein bound to regions within the promoter from −297 bp and
p53 antibody supershifted maspin bands. In support of these data, a later study (using tissue
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microarray analysis) reported an inverse relationship between mutated p53 and maspin in
human tumors [17]. The implication of maspin involvement in the p53 pathway demonstrated
a potential hierarchy of tumor suppressor pathways. Studies suggest that maspin may act as
an effector molecule downstream of the p53 stress-induced pathway. Interestingly, other
proteins and signaling pathways related to maspin regulation were reported to be dependent
on p53. Transforming growth factor β (TGFβ) was also found to increase maspin expression
and required wild-type p53 activity [18]. This work demonstrated two p53 binding sites in the
maspin promoter that were either in close proximity or overlapped with a Smad binding
element, leading to recruitment of Smad2/3 and p53 to the maspin promoter following TGFβ
signaling. In addition, Smad2/3 increased the binding of p53 to the maspin promoter demon‐
strating transcriptional co-regulation. Reports suggest that there are other factors that regulate
maspin expression, independent of p53 function. Expression of the antioxidant manganese
superoxide dismutase in prostate cells led to an increase in stability of maspin mRNA, and this
effect persisted in the presence of wild-type or mutant p53 [19]. Furthermore, the activating
transcription factor (ATF-2) was shown to induce maspin expression independently of p53 by
binding to a CRE-like sequence downstream of the transcription start site [20]. In addition,
other members of the p53 family, specifically the p63 isoform TAp63γ, induce expression of
maspin by binding to the same consensus p53 promoter element and can substitute for
activation in the absence of p53 [21]. Other transcription factors have also been noted to bind
to maspin promoter and regulate its expression as shown in Figure 2.
Figure 2. Regulation of maspin by various transcription factors. Maspin promoter has several transcription factor bind‐
ing sites that regulate its expression and function. Most of maspin regulation by the transcription factors is unclear, but
the regulation by p53 is widely studied and involves the TGF-β signaling.
Recent evidences suggest that maspin can be epigenetically regulated and that its expression
in relationship with tissue specificity directly correlates with DNA methylation [2, 22].
Treatment of maspin-null cancer cell lines with 5-aza-2′-deoxycytidine resulted in the induc‐
tion of maspin expression [22]. Furthermore, promoter methylation was found to serve as a
mechanism for tissue and cell-specific expression of maspin [2, 22]. Epigenetic changes
regulating maspin expression have been demonstrated to occur at the 5′ regulatory region of
the maspin gene that involves methylation of cytosine, histone deacetylation, and the acces‐
sibility of chromatin. Two defining epigenetic events are DNA methylation and histone lysine
methylation or deacetylation, which are categorized as chromatin modification events. In
support of this, we and others have shown that treatment of prostate cancer cell lines with
histone deacetylase (HDAC) inhibitors, namely sodium butyrate and trichostatin A, led to
induction of maspin at mRNA and protein level [23]. Re-expression of maspin using deme‐
thylating agents and HDAC inhibitors in combination has been confirmed in additional
studies. Furthermore, studies using prostate cancer cells and clinical specimens, we have
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further demonstrated that maspin expression was only induced by inhibition of class I histone
deacetylases regardless of promoter methylation status, highlighting that chromatin conden‐
sation alone may determine its transcriptional activity [23].
Maspin is a non-glycosylated protein; however, phosphorylated forms have been identified
and detected in various tumors [24]. Early studies demonstrate abundance of tyrosine
phosphorylation in both endogenously expressed maspin in normal epithelial cells and after
induction of maspin in transfected tumor cells [18]. Although the kinases responsible for this
phosphorylation have yet to be identified, incubation of rMaspin with the TKD38 EGFR kinase
domain led to tyrosine phosphorylation in a cell-free system. In addition, serine and threonine
phosphorylation sites have been recently identified on maspin secreted from cornea cells using
a mass spectrometry approach [25]. Whether this phenomenon is cell type specific requires
further studies. In addition to phosphorylation studies, maspin also contains eight cysteine
residues; however, intramolecular disulfide bonding had not previously been observed nor
predicted from maspin crystallography. Under oxidative stress, maspin adopted an oxidized,
disulfide-bonded structure, which was analyzed under non-reducing conditions in epithelial
cells [26]. In this state, maspin was no longer able to bind glutathione S-transferase (GST), a
binding partner for maspin, which suggested a potential difference in protein functionality.
4. Protein binding partners of maspin
Through the yeast two-hybrid assays, screening studies identified possible protein-protein
interactions with maspin [27]. A short list of candidate intracellular partners of maspin include
heat shock proteins (Hsp90 and Hsp70), glutathione S-transferase (GST), interferon regulatory
factor 6 (IRF6), histone deacetylase 1 (HDAC1), early growth response protein 1 (Egr-1), and
GC-binding factor 2 (GCF2). These studies provide new dimensions in understanding the role
of maspin from that of a serine protease inhibitory serpin to that of a stress-responsive
chaperone and role of maspin in tumor suppression.
Hsp90 is one of the most abundant stress-responsive chaperones that shuttle between the
cytoplasm and nucleus to protect its client proteins from degradation [28]. Hsp90 binds and
protects the native conformation of AR. AR attains activation and becomes functional as a
consequence of agonists binding to its receptor, or when phosphorylated by Akt or due to
mutation is ensued by its nuclear translocation. In the nucleus, AR employs co-activators that
facilitate its binding to the promoter sequence of responsive genes to activate their expression
[29]. Inhibition of Hsp90 destabilizes both wild type and mutant AR, presumably by releasing
AR from the chaperone complex, to be subjected to degradation by the proteasome. Once in
the nucleus, AR is acetylated, which may be mediated by its co-activators such as p300.
Acetylated AR has been shown to specifically interact with and be deacetylated by HDAC1
[30]. Reports suggest that molecular interactions of maspin with HDAC1 and/or Hsp90 may
underlie the positive correlation between nuclear maspin and better prognosis of cancer [31].
Inhibition of HDAC specifically upregulates genes that promote cell differentiation, cell cycle
arrest, or cell death and downregulates genes that promote tumor survival and epithelial-
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mesenchymal transition, which correlate with higher levels of maspin, whereas both Hsp90
and HDAC have been implicated as key regulators of AR activity and stability. Lockett et al.
have proposed a model where maspin may negatively regulate AR-dependent survival/
proliferation of both hormone-sensitive and hormone-refractory prostate epithelial cells [32].
This model proposes that genetic engineering approaches to induce maspin expression may
prove to be effective in blocking Hsp90-mediated stability, and/or HDAC1-mediated tran‐
scriptional activation, of AR in prostate cancer cells.
The maspin/GST interaction was initially characterized [27]. Endogenous maspin has been
shown to correlate with increased cellular GST activity, even though purified maspin does not
affect the activity of GST in vitro. Furthermore, maspin transfected tumor cells exhibit markedly
lower basal levels of ROS, compared to the control transfected cells. In contrast, siRNA
knockdown of maspin in prostate cancer PC-3 cells increased the basal ROS level. Tahmatzo‐
poulos et al. have shown that treatment of human prostate cancer DU145 cells with H2O2 (or
PMA) but not with TRAIL further increases the maspin/GST interaction and significantly
attenuated H2O2-induced ROS generation and VEGF expression [33]. This study further
demonstrates that maspin transfected tumor cells produced less VEGF than the transfection
control cells. Interestingly, a single point mutation at the RSL p1 position of maspin
(MasR340A) greatly reduced the affinity for GST. Consistently, treatment with purified wild-
type maspin, but not MasR340A, significantly increased cellular GST activity.
Studies by Bailey et al. reported specific interaction between maspin and interferon regulatory
factor 6 (IRF6) [34, 35]. IRF6 is a member of the IRF family associated with epithelial-to-
mesenchymal transition through increase in N-cadherin. The interaction between maspin and
IRF6 appears to be regulated by IRF6 phosphorylation and may negatively regulate the IRF6
activity. Other maspin-binding proteins identified by yeast two-hybrid approach include
transcription factors, such as early growth response protein 1 (Egr-1), GC-binding factor 2
(GCF2), and RNA-binding protein KHDRBS3 and FBX032, which are involved in ubiquitin
protein ligase reactions [25]. Additional studies to understand how these proteins interact with
maspin and their role during prostate cancer progression are needed.
5. Biological functions of maspin
Maspin downregulation correlates with increased tumor growth and metastasis [36]. Several
published studies using cell lines and animal models underscore the critical role of maspin in
tumor growth and invasion. Treatment with recombinant maspin protein was found to inhibit
tumor invasion and motility of prostate cancer cells (LNCaP, DU145, and PC-3) in culture by
binding specifically to the cell surface. This surface action was further supported by the ability
of maspin to block urokinase-type plasminogen activator on cell surface of prostate cancer
DU145 cells [5]. Cher et al. used a SCID human intraosseous tumor model that ectopically
overexpresses maspin in prostate cancer DU145 cells to demonstrate maspin’s ability to
abrogate bone matrix remodeling, repress bone tumor growth, and prevent angiogenesis [37].
In another study, Hall et al. using maspin overexpressed PC-3 tumor cells injected to athymic
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nude mice demonstrated a decrease in bone metastasis but failed to suppress the ability of
tumor cells spread/metastasize to distant sites providing new insight in the underlying
inhibitory role of tumor cell homing into the bone [38]. Interestingly, in genetically engineered
mouse model of prostate cancer, TRAMP the mechanism of maspin repression occurred
through association of receptor activator of NF-kB (RANK) with ligand RANKL that facilitates
IkB kinase α (IKKα) nuclear translocation, which in turn suppresses maspin transcription
allowing progression of prostate cancer [39].
The anti-angiogenic effects of maspin were demonstrated by Zhang et al. using endothelial
cells [40]. Increasing concentrations of rMaspin inhibited both the growth and migration of
endothelial cells toward vascular endothelial growth factor (VEGF) and basic fibroblast growth
factor (bFGF) in vitro. In vivo experiments using human prostate cancer LNCaP cells grown in
immunodeficient xenograft model, tumor growth and neovascularization were reduced
following rMaspin treatment [40]. A chimeric bone cancer model in which human cancer cells
were injected into human bone that had been implanted into SCID/SCID mice demonstrated
that DU145 human prostate cancer cells transfected with maspin exhibited less tumor neo‐
vascularization from murine endothelial cells compared to controls. This effect was associated
with a decrease in tumor growth and bone destruction [36, 37]. Another study demonstrated
that conditioned media (CM) from maspin-expressing human keratinocytes inhibited the
ability of human endothelial cells to migrate toward angiogenic factors, namely VEGF, bFGF,
and interleukin-8 (IL-8), in a dose-dependent manner [40]. Using maspin neutralizing antibody
to the CM, the cells resumed their ability to migrate, providing evidence for a paracrine anti-
angiogenic role of maspin.
Increased cell adhesion and cell-cell contact are negative factors for cell cycle progression.
Increased cell adhesion to ECM is shown to cause certain cell types to arrest in G1 phase [41].
Studies suggest that maspin has ability to increase prostate epithelial cell adhesion to different
matrix proteins and inhibit prostate tumor progression through increased cell adhesion to
matrices. Recent study provides evidence that maspin controls cell adhesion through its
interaction with integrin β1 [42]. Interestingly, loss of one copy of maspin gene in Maspin+/−
heterozygous knockout mice leads to the development of prostate hyperplastic lesions,
accompanied with a changed pattern of matrix deposition and a loss of epithelial cell polarity
[41]. It was also demonstrated that maspin may be able to inhibit surface-bound urokinase
plasminogen activator in prostate tumor cells. However, the aforementioned results were not
easily observed in vitro or in vivo. In vitro, tumor suppression was not observed with the use
of maspin, while in vivo, only 50% of tumors that expressed maspin showed a significant
reduction [36, 37].
Maspin has been observed to be involved in the regulation of apoptosis. Pro-apoptotic effects
from maspin have been demonstrated in prostate cancer cells. Studies by Mckenzie et al.
underline maspin as a pertinent therapeutic target to overcome hypoxia in prostate cancer.
Overexpression of maspin in DU145 cells leads to apoptosis by abrogating AKT activation
induced by hypoxia. According to recent studies, it has been shown that maspin expression
(endogenously) is able to sensitize prostate cancer LNCaP and DU145 cells to apoptosis [9].
Watanabe et al. used adeno-associated virus (AAV, serotype 2) vector encoding maspin as a
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means for introducing in vivo gene therapy subcutaneously formed human prostate cancer
LNCaP or DU145 tumors in nude mice [43]. In this study, intratumoral AAV-mediated maspin
expression significantly upregulated the number of apoptotic cells when compared with AAV-
LacZ treatment. Moreover, significantly fewer CD31-positive micro-vessels were observed in
AAV-maspin-treated tumors when compared with the control tumors, which correlated with
persistent maspin expression. Studies on mechanics have demonstrated that maspin could
possibly lead to apoptosis of tumor cells through the manipulation of mitochondrial permea‐
bility and the initiation of degradation through apoptosis [44]. Maspin has also been shown to
induce prostate tumor cell dedifferentiation and to increase tumor cell sensitivity to drug-
induced apoptosis. Suppression of maspin may partly be attributed to the involvement of AR
in prostate tumorigenesis and cancer progression. Maspin’s role as a tumor suppressor in
prostate cancer cells irrespective of their AR status makes it an ideal candidate with therapeutic
capabilities against hormone-refractory prostate cancer. Other biological functions of maspin
are listed in Figure 3.
Figure 3. Biological functions of maspin. Post-translational modification of maspin and its nuclear localization sup‐
presses angiogenesis, tumor metastasis, cell invasion, and migration and inhibits bone tumor growth and proliferation,
while inducing apoptosis.
6. Therapeutic application of maspin
Recent studies have investigated the anticancer effects of maspin expression and the use of
maspin as a therapeutic agent against cancer. Tumors with LNCaP cells expressing adeno-
viral maspin (AAV-GFP) resulted in a higher percentage of apoptotic cell death and a decrease
in the number of CD31 positive vessels when compared with tumors with empty vector (GFP),
thereby substantiating the role of maspin in gene therapy [44]. These results confirm maspin
as a therapeutic agent/target in inhibiting prostate cancer progression. Furthermore, animal
studies using targeted delivery of maspin by liposome/DNA and/or adenoviral constructs to
tumor and/or tumor vasculature have supported a viable approach in cancer treatment [45].
Several reports suggest that exogenously added rMaspin, or maspin-derived peptide frag‐
ments, can act at the surface of numerous migratory cell types to suppress cell motility and
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movement by enhancing cellular adhesion to the extracellular matrix components laminin,
fibronectin, and collagen [43, 45]. McGoven et al. have shown that purified recombinant
maspin produced in baculovirus-infected Spodoptera frugiperda Sf9 insect cells [rMaspin] binds
specifically to the surface of human prostate cancer DU145 cells, inhibits the DU145 cell
surface-bound uPA, and forms a stable complex. Similar results with rMaspin were observed
in in vivo studies transplanted with human prostate cells [5]. In fact, biological assays of
invasion by prostate tumor cells through Matrigel membranes and of motility have shown that
rMaspin inhibits invasion and migration of these cells [46].
Maspin expression in tumor cells can also be increased by the use of various phytochemicals.
He et al. have demonstrated that gum mastic, a natural resin, can upregulate maspin expression
in prostate cancer cells [47]. Gum mastic induced maspin mRNA and protein expression, as
well as maspin promoter activity in LNCaP and DU145 cells by suppressing ARE binding
activity and enhancing Sp1 binding activity, and the increased activity in the maspin promoter.
Sheth et al. have demonstrated that resveratrol (trans-3,49,5-trihydroxystilbene), a polyphe‐
nolic antioxidant found in peanuts, grapes, and red wine inhibits cell proliferation, induces
apoptosis of human prostate cancer cells mediated by increase in maspin levels through Akt/
miR-21 pathway [48]. Natural compound curcumin, a hydrophobic polyphenol derived from
turmeric (the rhizome of the herb Curcuma longa), has been shown to inhibit the AR gene
activity in androgen-responsive human prostate cancer LNCaP cells suppressing AR transac‐
tion, thereby affecting AR-regulated genes including maspin [49]. As AR negatively regulates
maspin expression, curcumin-mediated inhibition of AR may induce the expression of maspin
through a mechanism, which is presently unclear. Nevertheless, increased expression of
maspin occurs only in prostate cancer cells, which harbor wild-type p53. As p53 activates
maspin promoter by binding directly to its p53 consensus-binding site [16], we studied the
effect of apigenin, a natural plant flavone in potentially restoring p53-mediated maspin levels.
Exposure of LNCaP and 22Rv1 cells, harboring wild-type p53, with apigenin resulted in dose
dependent increase in maspin expression and p53 activation through acetylation at the Lys305
residue by inhibiting class I HDACs. Apigenin withdrawal in LNCaP cells caused loss of
maspin and p53 acetylation. Furthermore, proteasome inhibitor MG132 inhibited apigenin-
mediated proteasomal degradation of class I HDACs in these cells. The increased apigenin-
mediated p53 acetylation enhanced its binding on maspin promoter, which was associated
with decrease in tumor cell invasion and migration. Apigenin treatment also caused accumu‐
lation of acetylated histone H3 in total cellular chromatin, increasing accessibility to bind with
the promoter sequences of maspin, consistent with the effects elicited by HDAC inhibitor,
trichostatin A. Similar observations were noted after feeding apigenin to 22Rv1 tumor
xenograft implanted in nude mice [50]. Other natural compounds that have been reported to
enhance prostate cancer suppression and inhibit invasion and migration through upregulation
of maspin are tanshinone IIA and apple peel extract [51, 52].
A study by Jiang et al. revealed differential expression patterns of maspin mRNA and protein
expression following treatment of cancer cells with essential fatty acids (EFAs) [53]. Addition
of omega-6, EFAs arachidonic acid and α-linolenic acid had no effect on maspin expression,
while treatment with γ-linolenic acid led to rapid increase in maspin mRNA [53]. Consumption
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of γ-linolenic acid has been linked to many beneficial effects in humans. Interestingly in the
same study, another omega-6 EFA, linoleic acid, resulted in decreased maspin expression. This
study highlighted specific effects of EFAs on maspin that may have significant implications in
cancer biology as well as a role for maspin in lipid signaling and processing. Not surprisingly,
in vitro promoter activity study showed that, in addition to p53 [16], a list of stress-related
signals including DNA-damaging agents, cytotoxic drugs [16], peroxisome proliferator-
activated receptor-gamma [54], nitric oxide [55], and manganese superoxide dismutase
(MnSOD) [56] activates maspin expression. Consistently, several stress signals that induce
maspin expression also induced more differentiated phenotypes [16, 54–56]. Furthermore,
epigenetic treatment of prostate cancer cell lines with trichostatin A, a histone deacetylase
(HDAC) inhibitor, led to induction of maspin mRNA [20, 50]. Re-expression of maspin using
demethylating agents and HDAC inhibitors has been confirmed in additional studies [50, 57].
7. Conclusions and future directions
Much remains to be understood about the molecular mechanism(s) of action of maspin in the
normal prostate and during cancer progression. Studies in our laboratory are ongoing to
determine the post-translational modifications of maspin, which may help elucidate the role
of maspin in signaling pathways relevant to cell adhesion and angiogenesis. The ability of
maspin and its post-translationally modified forms to act as effective therapeutic agents in
prostate cancer is also being pursued. Additional studies are required to unravel the multi‐
faceted interrogation of how maspin expression can alter the malignant phenotype of some
cell types and not others. Nevertheless, recent findings and ongoing studies should encourage
researchers to continue to explore the molecular mechanisms underlying maspin’s biological
effects in prostate cancer.
Clinical studies performed this far in prostate cancer demonstrate the significance of maspin
expression as a useful prognostic and possibly predictive marker for patients undergoing
definitive therapy. Focusing on the malignancies in which maspin exhibited a positive
prognostic value, therapeutic approaches studied so far aimed to re-activate this dormant
tumor suppressor gene by transcription factors that regulate its expression and/or to identify
natural substances that can determine the activation and the expression of maspin or possibly
deliver this molecule in tumor cell through gene therapy capable of upregulating maspin in
an attempt to reduce invasiveness and the risk of metastasis. Maspin packaged as an adenoviral
construct or a liposomal DNA has been utilized to reduce tumors and tumor vasculatures in
in vivo studies corroborates as a feasible approach toward cancer therapy. Nevertheless, the
approach using viral vectors or liposomal DNA complexes is accompanied with several safety
and efficacy issues that modify their association upon interaction with serum components,
which is a subject of rigorous studies, and further evaluation is required through clinical trials.
The usefulness of rMaspin in targeted therapy is debatable because proteins undergo rapid
clearance from the body through proteolysis, liver clearance and filtered through the kidneys.
These issues can be resolved by the use of nanotechnology, which has provided a valuable
option for targeted delivery of genes, drugs, and proteins.
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Recently performed studies highlight reversible nature of epigenetic silencing of maspin in
prostate cancer, which offers a unique opportunity for therapeutic intervention by several
epigenetic modifiers. Considering the anti-angiogenic and pro-apoptotic properties of nuclear
maspin shown by recent studies, re-activated nuclear maspin in association with anti-
angiogenic or chemotherapeutic drugs may be effective in the treatment of advance-stage
prostate cancer. Undoubtedly, the challenges are numerous, but the prospects for improved
therapeutic approaches through maspin application for this debilitating disease could be
immense.
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